Cargando…
Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies
Epidermal growth factor receptor (EGFR) G724S mutation represents a resistance mechanism to first- and third-generation EGFR tyrosine kinase inhibitors. Limited data are available regarding the efficacy of afatinib in patients with non-small cell lung cancer (NSCLC) harboring G724S mutation, particu...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481291/ https://www.ncbi.nlm.nih.gov/pubmed/35979997 http://dx.doi.org/10.1097/CAD.0000000000001321 |
_version_ | 1784791231339954176 |
---|---|
author | Cortiula, Francesco Pelizzari, Giacomo Corvaja, Carla De Maglio, Giovanna Fasola, Gianpiero |
author_facet | Cortiula, Francesco Pelizzari, Giacomo Corvaja, Carla De Maglio, Giovanna Fasola, Gianpiero |
author_sort | Cortiula, Francesco |
collection | PubMed |
description | Epidermal growth factor receptor (EGFR) G724S mutation represents a resistance mechanism to first- and third-generation EGFR tyrosine kinase inhibitors. Limited data are available regarding the efficacy of afatinib in patients with non-small cell lung cancer (NSCLC) harboring G724S mutation, particularly after osimertinib. A patient diagnosed with advanced EGFR-mutated (exon 19 deletion) NSCLC after several lines of treatment – gefitinib, osimertinib, heat shock protein inhibitors and chemotherapy-developed EGFR G724S mutation retaining the exon 19 deletion. She was then treated successfully with afatinib leading to a progression free survival of 9 months (and counting). This is the first report of the emergence of G724S mutation, together with ex19del, after three subsequent lines of therapy following progressive disease to Osimertinib, and we report for the first time the activity of afatinib against EGFR exon 18 G724S mutation in this setting. |
format | Online Article Text |
id | pubmed-9481291 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-94812912022-09-21 Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies Cortiula, Francesco Pelizzari, Giacomo Corvaja, Carla De Maglio, Giovanna Fasola, Gianpiero Anticancer Drugs Case Reports Epidermal growth factor receptor (EGFR) G724S mutation represents a resistance mechanism to first- and third-generation EGFR tyrosine kinase inhibitors. Limited data are available regarding the efficacy of afatinib in patients with non-small cell lung cancer (NSCLC) harboring G724S mutation, particularly after osimertinib. A patient diagnosed with advanced EGFR-mutated (exon 19 deletion) NSCLC after several lines of treatment – gefitinib, osimertinib, heat shock protein inhibitors and chemotherapy-developed EGFR G724S mutation retaining the exon 19 deletion. She was then treated successfully with afatinib leading to a progression free survival of 9 months (and counting). This is the first report of the emergence of G724S mutation, together with ex19del, after three subsequent lines of therapy following progressive disease to Osimertinib, and we report for the first time the activity of afatinib against EGFR exon 18 G724S mutation in this setting. Lippincott Williams & Wilkins 2022-08-12 2022-10 /pmc/articles/PMC9481291/ /pubmed/35979997 http://dx.doi.org/10.1097/CAD.0000000000001321 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Case Reports Cortiula, Francesco Pelizzari, Giacomo Corvaja, Carla De Maglio, Giovanna Fasola, Gianpiero Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies |
title | Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies |
title_full | Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies |
title_fullStr | Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies |
title_full_unstemmed | Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies |
title_short | Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies |
title_sort | non-small cell lung cancer harboring egfr g724s mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481291/ https://www.ncbi.nlm.nih.gov/pubmed/35979997 http://dx.doi.org/10.1097/CAD.0000000000001321 |
work_keys_str_mv | AT cortiulafrancesco nonsmallcelllungcancerharboringegfrg724smutationandexon19deletionrespondedtoafatinibmonotherapyaftermultiplelinesoftargettherapies AT pelizzarigiacomo nonsmallcelllungcancerharboringegfrg724smutationandexon19deletionrespondedtoafatinibmonotherapyaftermultiplelinesoftargettherapies AT corvajacarla nonsmallcelllungcancerharboringegfrg724smutationandexon19deletionrespondedtoafatinibmonotherapyaftermultiplelinesoftargettherapies AT demagliogiovanna nonsmallcelllungcancerharboringegfrg724smutationandexon19deletionrespondedtoafatinibmonotherapyaftermultiplelinesoftargettherapies AT fasolagianpiero nonsmallcelllungcancerharboringegfrg724smutationandexon19deletionrespondedtoafatinibmonotherapyaftermultiplelinesoftargettherapies |